An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Dolutegravir/rilpivirine (Primary) ; Dolutegravir; Rilpivirine
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 25 Oct 2016 Status changed from recruiting to completed.
- 17 Oct 2016 Planned number of patients changed from 86 to 118.
- 08 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016.